View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
November 6, 2020

Coronavirus company news summary – NeuroRx and Relief’s allowed to fully enrol RLF-100 trial – Bangladesh signs access agreement with SII

By Allie Nawrat

6 November 2020 

Celltrion announced safety and efficacy results from the Phase I clinical trial of CT-P59 on mild Covid-19 patients. The biopharmaceutical company announced these results at a recent conference of the Korean Society of Infectious Diseases and Korean Antimicrobial Therapeutics.

NeuroRx and Relief Therapeutics announced that the independent Data Monitoring Committee has voted for the full enrolment of 165 patients for the Phase IIb/III NCT 04311697 study.  The committee cited no issues with safety and believed that the study could reach its prespecified endpoint, proving that RLF-100 allows critical Covid-19 patients to achieve recovery from respiratory failure.

Arch Biopartners announced that it had begun dosing patients with its LSALT peptide drug in a Phase II trial in Turkey. The drug targets acute injury to the lungs, kidney, and other complications caused by inflammation among moderate to severely affected hospitalised Covid-19 patients.

The government of Bangladesh signed a memorandum of understanding with the Serum Institute of India (SII) and Bexmico Pharmaceuticals to procure 30 million doses of Covishield, a Covid-19 vaccine being developed by the University of Oxford, AstraZeneca and the SII. Once developed, five million doses of the vaccine will be purchased through Bexmico every month, according to the Health Minister.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology